Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
212Pb-DARPin-DLL3
- Development stage
- Preclinical
- Lead developer
- Molecular Partners
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
212Pb-DARPin-DLL3 (MP0712) is a preclinical-stage targeted alpha therapy (TAT) being developed by Orano Med in partnership with Molecular Partners. The drug consists of a Designed Ankyrin Repeat Protein (DARPin) binder specific for Delta-like ligand 3 (DLL3) conjugated to a Lead-212 (212Pb) radioactive payload. DLL3 is an inhibitory Notch ligand that is highly expressed on the surface of small-cell lung cancer (SCLC) and other neuroendocrine tumor cells, while remaining largely absent in healthy tissues. By utilizing the DARPin platform, the therapeutic achieves high specificity and rapid tumor penetration. The 212Pb isotope acts as an alpha-particle emitter, delivering high-energy radiation to induce double-strand DNA breaks in tumor cells, leading to cell death with minimal impact on surrounding healthy tissue.
- Other names
- MP0712MP-0712MP 0712212Pb-DARPin-DLL3Lead-212-labeled DARPin targeting DLL3Lead212-labeled DARPin targeting DLL3Lead 212-labeled DARPin targeting DLL3
02
Targets
DLL3 (Delta-like ligand 3)
Beyond the preview
Go deeper on 212Pb-DARPin-DLL3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 212Pb-DARPin-DLL3.